N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6

The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively deco...

Full description

Saved in:
Bibliographic Details
Published inMicrobiology and immunology Vol. 68; no. 5; pp. 165 - 178
Main Authors Das, Tuhin, Luo, Shuhong, Tang, Hao, Fang, Jianmin, Mao, Yinging, Yen, Haw‐Han, Dash, Sabyasachi, Shajahan, Asif, Pepi, Lauren, Huang, Steven, Jones, Valerie S., Xie, Shehuo, Huang, Gordon F., Lu, Jinqiao, Anderson, Blake, Zhang, Benyue, Azadi, Parastoo, Huang, Ruo‐Pan
Format Journal Article
LanguageEnglish
Published Australia 01.05.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively decorated with up to 66 N‐linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N‐glycosylation at Asn331 and Asn343 of SARS‐CoV‐2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS‐CoV‐2 spike protein into cells. Interestingly, high‐content glycan binding screening data have shown that N‐glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ−1,4 GlcNAc), which is critical for spike‐RBD‐ACE2 binding. Furthermore, IL‐6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N‐glycosylation of Asn331 and Asn343 sites of the spike receptor‐binding domain (RBD) significantly reduced the transcriptional upregulation of pro‐inflammatory signaling molecule IL‐6. In addition, IL‐6 levels correlated with spike protein levels in COVID‐19 patients' serum. These findings establish the importance of RBD glycosylation in SARS‐CoV‐2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID‐19.
AbstractList The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS‐CoV‐2 spike protein is extensively decorated with up to 66 N‐linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N‐glycosylation at Asn331 and Asn343 of SARS‐CoV‐2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS‐CoV‐2 spike protein into cells. Interestingly, high‐content glycan binding screening data have shown that N‐glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ−1,4 GlcNAc), which is critical for spike‐RBD‐ACE2 binding. Furthermore, IL‐6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N‐glycosylation of Asn331 and Asn343 sites of the spike receptor‐binding domain (RBD) significantly reduced the transcriptional upregulation of pro‐inflammatory signaling molecule IL‐6. In addition, IL‐6 levels correlated with spike protein levels in COVID‐19 patients' serum. These findings establish the importance of RBD glycosylation in SARS‐CoV‐2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID‐19.
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global public health crisis. The causative agent, the SARS-CoV-2 virus, enters host cells via molecular interactions between the viral spike protein and the host cell ACE2 surface protein. The SARS-CoV-2 spike protein is extensively decorated with up to 66 N-linked glycans. Glycosylation of viral proteins is known to function in immune evasion strategies but may also function in the molecular events of viral entry into host cells. Here, we show that N-glycosylation at Asn331 and Asn343 of SARS-CoV-2 spike protein is required for it to bind to ACE2 and for the entry of pseudovirus harboring the SARS-CoV-2 spike protein into cells. Interestingly, high-content glycan binding screening data have shown that N-glycosylation of Asn331 and Asn343 of the RBD is important for binding to the specific glycan molecule G4GN (Galβ-1,4 GlcNAc), which is critical for spike-RBD-ACE2 binding. Furthermore, IL-6 was identified through antibody array analysis of conditioned media of the corresponding pseudovirus assay. Mutation of N-glycosylation of Asn331 and Asn343 sites of the spike receptor-binding domain (RBD) significantly reduced the transcriptional upregulation of pro-inflammatory signaling molecule IL-6. In addition, IL-6 levels correlated with spike protein levels in COVID-19 patients' serum. These findings establish the importance of RBD glycosylation in SARS-CoV-2 pathogenesis, which can be exploited for the development of novel therapeutics for COVID-19.
Author Lu, Jinqiao
Anderson, Blake
Luo, Shuhong
Huang, Steven
Zhang, Benyue
Mao, Yinging
Dash, Sabyasachi
Shajahan, Asif
Tang, Hao
Yen, Haw‐Han
Jones, Valerie S.
Pepi, Lauren
Das, Tuhin
Xie, Shehuo
Huang, Ruo‐Pan
Azadi, Parastoo
Fang, Jianmin
Huang, Gordon F.
Author_xml – sequence: 1
  givenname: Tuhin
  orcidid: 0000-0001-8202-0838
  surname: Das
  fullname: Das, Tuhin
  organization: RayBiotech Life Inc
– sequence: 2
  givenname: Shuhong
  orcidid: 0000-0002-9058-4833
  surname: Luo
  fullname: Luo, Shuhong
  organization: RayBiotech Guangzhou Co. Ltd. Guangzhou
– sequence: 3
  givenname: Hao
  surname: Tang
  fullname: Tang, Hao
  organization: RayBiotech Guangzhou Co. Ltd. Guangzhou
– sequence: 4
  givenname: Jianmin
  surname: Fang
  fullname: Fang, Jianmin
  organization: RayBiotech Guangzhou Co. Ltd. Guangzhou
– sequence: 5
  givenname: Yinging
  orcidid: 0009-0004-2193-7983
  surname: Mao
  fullname: Mao, Yinging
  organization: RayBiotech Life Inc
– sequence: 6
  givenname: Haw‐Han
  surname: Yen
  fullname: Yen, Haw‐Han
  organization: RayBiotech Life Inc
– sequence: 7
  givenname: Sabyasachi
  orcidid: 0000-0003-3966-9396
  surname: Dash
  fullname: Dash, Sabyasachi
  organization: Center for Vascular Biology, Weill Cornell Medicine
– sequence: 8
  givenname: Asif
  orcidid: 0000-0002-4804-1130
  surname: Shajahan
  fullname: Shajahan, Asif
  organization: Vaccine Research Center
– sequence: 9
  givenname: Lauren
  orcidid: 0000-0002-5740-4175
  surname: Pepi
  fullname: Pepi, Lauren
  organization: Vaccine Research Center
– sequence: 10
  givenname: Steven
  surname: Huang
  fullname: Huang, Steven
  organization: RayBiotech Life Inc
– sequence: 11
  givenname: Valerie S.
  orcidid: 0000-0002-4204-9959
  surname: Jones
  fullname: Jones, Valerie S.
  organization: RayBiotech Life Inc
– sequence: 12
  givenname: Shehuo
  surname: Xie
  fullname: Xie, Shehuo
  organization: RayBiotech Guangzhou Co. Ltd. Guangzhou
– sequence: 13
  givenname: Gordon F.
  surname: Huang
  fullname: Huang, Gordon F.
  organization: RayBiotech Life Inc
– sequence: 14
  givenname: Jinqiao
  surname: Lu
  fullname: Lu, Jinqiao
  organization: RayBiotech Life Inc
– sequence: 15
  givenname: Blake
  orcidid: 0000-0003-3237-9046
  surname: Anderson
  fullname: Anderson, Blake
  organization: RayBiotech Life Inc
– sequence: 16
  givenname: Benyue
  orcidid: 0000-0002-3610-3517
  surname: Zhang
  fullname: Zhang, Benyue
  organization: RayBiotech Life Inc
– sequence: 17
  givenname: Parastoo
  orcidid: 0000-0002-6166-9432
  surname: Azadi
  fullname: Azadi, Parastoo
  organization: University of Georgia
– sequence: 18
  givenname: Ruo‐Pan
  orcidid: 0000-0002-5884-8026
  surname: Huang
  fullname: Huang, Ruo‐Pan
  email: rhuang@raybiotech.com
  organization: Guangzhou Medical University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38444370$$D View this record in MEDLINE/PubMed
BookMark eNpFkEtOwzAURS0Eoh8YM0NeQFNsP-c3jKIClVqQKDCN8nGKIXWiOC3KjCUwYYOsBCeF4oF95XePLZ0ROlalEghdUDKlZl1R4J5FOKNTCpTRIzQ83ByjIQHPtmyHkAEaaf1KCHOZx0_RADzOObhkiL7uvj8-10Wblrot4kaWCpc5bl4EXgUPKzMLy2ezM6wr-SZwVZeNkArHDQ60AqA4VlkfOWCpsVS7stiJzIQ9YdggnDGcSJVJtZ7gnay3GgvV1O2kh2ux3v7_PF8YwjlDJ3lcaHH-e47R0_XsMby1Fvc38zBYWCn3GbVY4mdAiW0nxM0AIHac1MszN3FTwU0DXN_mwo49F2LXzr2OShgI40EIJ_NhjC7371bbZCOyqKrlJq7b6M-PKdj7wrssRHuYUxJ1-qNOdtTJjnr90XK-7AP8APneez0
CitedBy_id crossref_primary_10_3390_life15020162
ContentType Journal Article
Copyright 2024 The Authors. published by The Societies and John Wiley & Sons Australia, Ltd.
2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.
Copyright_xml – notice: 2024 The Authors. published by The Societies and John Wiley & Sons Australia, Ltd.
– notice: 2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.
DBID 24P
CGR
CUY
CVF
ECM
EIF
NPM
DOI 10.1111/1348-0421.13121
DatabaseName Wiley Online Library Open Access (Activated by CARLI)
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
DatabaseTitleList
MEDLINE
Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access (Activated by CARLI)
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 1348-0421
EndPage 178
ExternalDocumentID 38444370
MIM13121
Genre article
Journal Article
GrantInformation_xml – fundername: National Institutes of Health (NIH)
  funderid: R24GM137782‐01
– fundername: NIGMS NIH HHS
  grantid: R24 GM137782
– fundername: National Institutes of Health (NIH)
  grantid: R24GM137782-01
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
123
1OC
24P
29M
2WC
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52S
52T
52U
52W
52X
53G
5HH
5LA
5RE
5VS
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A03
A8Z
AAESR
AAEVG
AAHHS
AAHQN
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAZKR
ABCUV
ABJNI
ABPVW
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFO
ACGFS
ACPOU
ACPRK
ACRPL
ACXBN
ACXQS
ACYXJ
ADBBV
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFFNX
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHMBA
AIAGR
AITYG
AIURR
AIWBW
AJBDE
AJXKR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ATUGU
AUFTA
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMNLL
BMXJE
BNHUX
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-E
D-F
DCZOG
DIK
DPXWK
DRFUL
DRSTM
DU5
E3Z
EBD
EBS
EJD
EMB
EMOBN
F00
F01
F04
F5P
FEDTE
G-S
G.N
GODZA
H.T
H.X
HF~
HGLYW
HVGLF
HZ~
J0M
JSF
JSH
KQ8
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MM.
MRFUL
MRSTM
MSFUL
MSSTM
MXFUL
MXSTM
N04
N05
N9A
NF~
O66
O9-
OHT
OIG
OK1
OVD
P2P
P2W
P2X
P4D
PQQKQ
Q.N
Q11
QB0
R.K
RJT
ROL
RX1
RZJ
SJN
SUPJJ
SV3
TEORI
TKC
TWZ
UB1
V8K
W8V
W99
WBKPD
WHG
WIH
WIK
WIN
WNSPC
WOHZO
WXSBR
WYISQ
X7M
XG1
XOL
XSB
ZGI
ZXP
ZZTAW
~IA
~WT
AAMMB
AEFGJ
AEYWJ
AGHNM
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
OVT
ID FETCH-LOGICAL-c4921-2b9d31055b07d333a66c8fd7b7ce449237954e5a873a75f8c492b23e027ee6d93
IEDL.DBID 24P
ISSN 0385-5600
IngestDate Mon Jul 21 05:57:13 EDT 2025
Wed Jan 22 17:19:13 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords ACE2
COVID‐19
SARS‐CoV‐2
receptor‐binding domain
spike protein
N‐glycosylation
IL‐6
Language English
License Attribution
2024 The Authors. Microbiology and Immunology published by The Societies and John Wiley & Sons Australia, Ltd.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4921-2b9d31055b07d333a66c8fd7b7ce449237954e5a873a75f8c492b23e027ee6d93
Notes Tuhin Das, Shuhong Luo, and Hao Tang contributed equally to this study.
ORCID 0000-0002-4204-9959
0000-0003-3237-9046
0000-0002-6166-9432
0000-0003-3966-9396
0000-0001-8202-0838
0009-0004-2193-7983
0000-0002-3610-3517
0000-0002-5740-4175
0000-0002-5884-8026
0000-0002-4804-1130
0000-0002-9058-4833
OpenAccessLink https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1348-0421.13121
PMID 38444370
PageCount 14
ParticipantIDs pubmed_primary_38444370
wiley_primary_10_1111_1348_0421_13121_MIM13121
PublicationCentury 2000
PublicationDate May 2024
PublicationDateYYYYMMDD 2024-05-01
PublicationDate_xml – month: 05
  year: 2024
  text: May 2024
PublicationDecade 2020
PublicationPlace Australia
PublicationPlace_xml – name: Australia
PublicationTitle Microbiology and immunology
PublicationTitleAlternate Microbiol Immunol
PublicationYear 2024
References 2021; 6
2021; 21
2021; 20
2021; 4
2020; 20
2020; 383
2010; 169
2021; 128
2020; 181
2020; 182
2019; 15
2020; 369
2020; 588
2020; 16
2020; 15
2019; 18
2021; 384
2020; 584
2020; 11
2020; 146
2020; 367
2020; 10
2014; 40
2015; 7
2019; 145
2007; 15
2013; 9
2020; 18
2021; 35
2015; 23
2021; 13
2015; 25
2021; 31
2003; 348
2021; 12
2020; 2
2021; 433
2021; 118
2018; 92
2020; 28
2020; 116
2020; 26
2017
2020; 257
2012; 4
2022; 503
2016; 23
References_xml – volume: 369
  start-page: 330
  issue: 6501
  year: 2020
  end-page: 333
  article-title: Site‐specific glycan analysis of the SARS‐CoV‐2 spike
  publication-title: Science
– volume: 20
  start-page: 533
  issue: 5
  year: 2020
  end-page: 534
  article-title: An interactive web‐based dashboard to track COVID‐19 in real time
  publication-title: Lancet Infect Dis
– volume: 20
  year: 2021
  article-title: Site‐specific N‐glycosylation characterization of recombinant SARS‐CoV‐2 spike proteins
  publication-title: Mol Cell Proteomics
– volume: 12
  year: 2021
  article-title: The importance of glycans of viral and host proteins in enveloped virus infection
  publication-title: Front Immunol
– volume: 4
  start-page: 1011
  issue: 6
  year: 2012
  end-page: 1033
  article-title: Mechanisms of coronavirus cell entry mediated by the viral spike protein
  publication-title: Viruses
– volume: 588
  start-page: 682
  year: 2020
  end-page: 687
  article-title: SARS‐CoV‐2 neutralizing antibody structures inform therapeutic strategies
  publication-title: Nature
– volume: 11
  year: 2020
  article-title: Variations in SARS‐CoV‐2 spike protein cell epitopes and glycosylation profiles during global transmission course of COVID‐19
  publication-title: Front Immunol
– volume: 181
  start-page: 281
  issue: 2
  year: 2020
  end-page: 292
  article-title: Structure, Function, and Antigenicity of the SARS‐CoV‐2 Spike Glycoprotein
  publication-title: Cell
– volume: 18
  start-page: 179
  issue: 1
  year: 2020
  article-title: Emerging SARS‐CoV‐2 mutation hot spots include a novel RNA‐dependent‐RNA polymerase variant
  publication-title: J Transl Med
– volume: 367
  start-page: 1260
  issue: 6483
  year: 2020
  end-page: 1263
  article-title: Cryo‐EM structure of the 2019‐nCoV spike in the prefusion conformation
  publication-title: Science
– volume: 348
  start-page: 1953
  issue: 20
  year: 2003
  end-page: 1966
  article-title: A novel coronavirus associated with severe acute respiratory syndrome
  publication-title: N Engl J Med
– volume: 2
  issue: 2
  year: 2020
  article-title: SARS‐CoV‐2 and COVID‐19: Is interleukin‐6 (IL‐6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc
  publication-title: Cytokine: X
– volume: 584
  start-page: 443
  issue: 7821
  year: 2020
  end-page: 449
  article-title: Potently neutralizing and protective human antibodies against SARS‐CoV‐2
  publication-title: Nature
– start-page: 149
  year: 2017
  end-page: 158
– volume: 15
  start-page: 346
  issue: 6
  year: 2019
  end-page: 366
  article-title: Glycosylation in health and disease
  publication-title: Nat Rev Nephrol
– volume: 11
  year: 2020
  article-title: Comparative Review of SARS‐CoV‐2, SARS‐CoV, MERS‐CoV, and influenza A respiratory viruses
  publication-title: Front Immunol
– volume: 28
  start-page: 586
  issue: 4
  year: 2020
  end-page: 601
  article-title: Virus‐Receptor Interactions of Glycosylated SARS‐CoV‐2 Spike and Human ACE2 Receptor
  publication-title: Cell Host Microbe
– volume: 169
  start-page: 365
  issue: 2
  year: 2010
  end-page: 374
  article-title: Generation of VSV pseudotypes using recombinant ΔG‐VSV for studies on virus entry, identification of entry inhibitors, and immune responses to vaccines
  publication-title: J Virol Methods
– volume: 146
  year: 2020
  article-title: The SARS‐CoV‐2 spike protein alters barrier function in 2D static and 3D microfluidic in‐vitro models of the human blood‐brain barrier
  publication-title: Neurobiol Dis
– volume: 584
  start-page: 437
  issue: 7821
  year: 2020
  end-page: 442
  article-title: Convergent antibody responses to SARS‐CoV‐2 in convalescent individuals
  publication-title: Nature
– volume: 92
  issue: 4
  year: 2018
  article-title: Glycan Shield and Fusion Activation of a Deltacoronavirus Spike Glycoprotein Fine‐Tuned for Enteric Infections
  publication-title: J Virol
– volume: 25
  start-page: 1323
  issue: 12
  year: 2015
  end-page: 1324
  article-title: Symbol Nomenclature for Graphical Representations of Glycans
  publication-title: Glycobiology
– volume: 12
  year: 2021
  article-title: Interleukin‐6 Is a biomarker for the development of fatal severe acute respiratory syndrome coronavirus 2 pneumonia
  publication-title: Front Immunol
– volume: 7
  start-page: 1700
  issue: 4
  year: 2015
  end-page: 1725
  article-title: Incorporation of spike and membrane glycoproteins into coronavirus virions
  publication-title: Viruses
– volume: 182
  start-page: 1284
  issue: 5
  year: 2020
  end-page: 1294
  article-title: The impact of mutations in SARS‐CoV‐2 spike on viral infectivity and antigenicity
  publication-title: Cell
– volume: 4
  start-page: 475
  issue: 1
  year: 2021
  article-title: Human ACE2 receptor polymorphisms and altered susceptibility to SARS‐CoV‐2
  publication-title: Commun Biol
– volume: 31
  start-page: 410
  issue: 4
  year: 2021
  end-page: 424
  article-title: Comprehensive characterization of N‐ and O‐ glycosylation of SARS‐CoV‐2 human receptor angiotensin converting enzyme 2
  publication-title: Glycobiology
– volume: 145
  year: 2019
  article-title: Production of pseudotyped particles to study highly pathogenic coronaviruses in a biosafety level 2 setting
  publication-title: J Vis Exp
– volume: 118
  issue: 19
  year: 2021
  article-title: Dual nature of human ACE2 glycosylation in binding to SARS‐CoV‐2 spike
  publication-title: Proc Natl Acad Sci
– volume: 40
  start-page: 785
  year: 2014
  end-page: 794
  article-title: Viral Interactions with Glycans
  publication-title: Glycosci: Biol Med
– volume: 23
  start-page: 899
  issue: 10
  year: 2016
  end-page: 905
  article-title: Glycan shield and epitope masking of a coronavirus spike protein observed by cryo‐electron microscopy
  publication-title: Nat Struct Mol Biol
– volume: 35
  start-page: 3026
  issue: 10
  year: 2021
  end-page: 3029
  article-title: An evidence that SARS‐Cov‐2/COVID‐19 spike protein (SP) damages hematopoietic stem/progenitor cells in the mechanism of pyroptosis in Nlrp3 inflammasome‐dependent manner
  publication-title: Leukemia
– volume: 384
  start-page: 1564
  issue: 16
  year: 2021
  end-page: 1565
  article-title: Interleukin‐6 receptor inhibition in Covid‐19—cooling the inflammatory soup
  publication-title: N Engl J Med
– volume: 15
  start-page: 817
  issue: 12
  year: 2020
  end-page: 822
  article-title: Relationship between IL‐6 and COVID‐19: to be considered during treatment
  publication-title: Future Virol
– volume: 503
  year: 2022
  article-title: The spike‐ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS‐CoV‐2 inhibitors and neutralizing antibodies
  publication-title: J Immunol Methods
– volume: 18
  start-page: 2348
  issue: 12
  year: 2019
  end-page: 2358
  article-title: Why glycosylation matters in building a better flu vaccine
  publication-title: Mol Cell Proteomics
– volume: 369
  start-page: 1261
  issue: 6508
  year: 2020
  end-page: 1265
  article-title: Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2
  publication-title: Science
– volume: 13
  start-page: 963
  issue: 10
  year: 2021
  end-page: 968
  article-title: A glycan gate controls opening of the SARS‐CoV‐2 spike protein
  publication-title: Nat Chem
– volume: 128
  start-page: 1323
  issue: 9
  year: 2021
  end-page: 1326
  article-title: SARS‐CoV‐2 spike protein impairs endothelial function via downregulation of ACE 2
  publication-title: Circ Res
– volume: 16
  issue: 12
  year: 2020
  article-title: SARS‐CoV‐2 spike protein promotes IL‐6 trans‐signaling by activation of angiotensin II receptor signaling in epithelial cells
  publication-title: PLoS Pathog
– volume: 383
  start-page: 1813
  issue: 19
  year: 2020
  end-page: 1826
  article-title: Remdesivir for the treatment of Covid‐19—final report
  publication-title: N Engl J Med
– volume: 181
  start-page: 271
  issue: 2
  year: 2020
  end-page: 280
  article-title: SARS‐CoV‐2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor
  publication-title: Cell
– volume: 584
  start-page: 450
  issue: 7821
  year: 2020
  end-page: 456
  article-title: Potent neutralizing antibodies against multiple epitopes on SARS‐CoV‐2 spike
  publication-title: Nature
– volume: 11
  start-page: 11
  year: 2020
  article-title: Evaluation of neutralizing antibodies against highly pathogenic coronaviruses: a detailed protocol for a rapid evaluation of neutralizing antibodies using vesicular stomatitis virus pseudovirus‐based assay
  publication-title: Front Microbiol
– volume: 9
  start-page: 776
  issue: 12
  year: 2013
  end-page: 784
  article-title: Adaptive immune activation: glycosylation does matter
  publication-title: Nat Chem Biol
– volume: 10
  issue: 1
  year: 2020
  article-title: Analysis of the SARS‐CoV‐2 spike protein glycan shield reveals implications for immune recognition
  publication-title: Sci Rep
– volume: 23
  start-page: 630
  issue: 10
  year: 2015
  end-page: 641
  article-title: Sweet talk: protein glycosylation in bacterial interaction with the host
  publication-title: TIM
– volume: 433
  issue: 4
  year: 2021
  article-title: Subtle influence of ACE2 glycan processing on SARS‐CoV‐2 recognition
  publication-title: J Mol Biol
– volume: 257
  year: 2020
  article-title: The bio‐mission of interleukin‐6 in the pathogenesis of COVID‐19: a brief look at potential therapeutic tactics
  publication-title: Life Sci
– volume: 21
  start-page: 337
  issue: 6
  year: 2021
  end-page: 339
  article-title: Is IL‐6 a key cytokine target for therapy in COVID‐19?
  publication-title: Nat Rev Immunol
– volume: 6
  start-page: 396
  issue: 1
  year: 2021
  article-title: The glycosylation in SARS‐CoV‐2 and its receptor ACE2
  publication-title: Signal Transduct Target Ther
– volume: 116
  start-page: 2207
  issue: 14
  year: 2020
  end-page: 2215
  article-title: SARS‐CoV‐2 infects and induces cytotoxic effects in human cardiomyocytes
  publication-title: Cardiovasc Res
– volume: 15
  start-page: 211
  issue: 5
  year: 2007
  end-page: 218
  article-title: Virus glycosylation: role in virulence and immune interactions
  publication-title: TIM
– volume: 26
  year: 2020
  article-title: Serum interleukin‐6 concentrations and the severity of COVID‐19 pneumonia: a retrospective study at a single center in Bengbu City, Anhui Province, China, in January and February 2020
  publication-title: Med Sci Monit
– volume: 369
  start-page: 643
  issue: 6504
  year: 2020
  end-page: 650
  article-title: Potent neutralizing antibodies from COVID‐19 patients define multiple targets of vulnerability
  publication-title: Science
SSID ssj0027284
Score 2.3864574
Snippet The coronavirus disease 2019 (COVID‐19) pandemic is an ongoing global public health crisis. The causative agent, the SARS‐CoV‐2 virus, enters host cells via...
The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global public health crisis. The causative agent, the SARS-CoV-2 virus, enters host cells via...
SourceID pubmed
wiley
SourceType Index Database
Publisher
StartPage 165
SubjectTerms ACE2
Angiotensin-Converting Enzyme 2 - metabolism
Asparagine - metabolism
COVID-19 - metabolism
COVID-19 - virology
COVID‐19
Glycosylation
HEK293 Cells
Humans
IL‐6
Interleukin-6 - metabolism
N‐glycosylation
Polysaccharides - metabolism
Protein Binding
receptor‐binding domain
SARS-CoV-2 - metabolism
SARS-CoV-2 - physiology
SARS‐CoV‐2
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - metabolism
spike protein
Virus Internalization
Title N‐glycosylation of the SARS‐CoV‐2 spike protein at Asn331 and Asn343 is involved in spike‐ACE2 binding, virus entry, and regulation of IL‐6
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2F1348-0421.13121
https://www.ncbi.nlm.nih.gov/pubmed/38444370
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LSwMxEA6iCF7E91ty8OhK89hN9liKpRVbilrxtmw2iSzKVrpV6M2f4MU_6C9xktRavHkJgTBZyLyXmW8QOsu1KZKG5ZF2mQ54CB0pCJQhS5EGBMoWVLgG514_6Qz51UP8U03oemECPsT8h5vTDG-vnYLnql5QcsK4jEDkyAVhxLWSr7gGWwefT_ngN-eiMiBIyThyzn2G7uOKef5csOCCFsNU72faG2h9FiDiZuDoJloy1RZaDSMjp9vos__1_vH4PC1G9TSUseGRxRDF4dvmzS2ctUb3sFJcv5RPBnsYhrLC-QQ364oxgvNK-y1nuKxxWYF5ejMaNoECaJutS4pV6dtdzvFbOX6tsZ8_cu6Jx2F6_ezL3WugSHbQsH151-pEs9EKUcFTSiKqUs3cbEzVEJoxlidJIa0WShSGO8w2kcbcxLkULBexlY5KUWbgQY1JdMp20XI1qsw-wiKVxFLNDbeW29TmxKYJj4niBGxFag_QXnjX7CXgZ2RMcs6ZaBygwOD5wU9C4jiTOc5knjNZr9vzm8P_EhyhNQpBSChQPEbLk_GrOYEgYqJOvZjA2h_0vgHUgr-L
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LS8MwHA-iiF7E91tz8LjKkvzbpMcxlE23IW6Kt9I2iRSlk3UKu_kRvPgF_STmMefw5qUEwi-F_N_h_0DoLJUqj-oaAmkjHWMhZJAZR9lEKUIZhtI55bbAuduLWndw9RA-zNXC-P4Qswc3KxlOX1sBtw_Sc1JOGIjA8Bw5J4zYWvIliCi3wknh5jfoosK3kBJhYK37tL2Pzeb5c8CcDZr3U52huVxHa1MPETc8STfQgio30bKfGTnZQp-9r_ePx-dJPqwmPo8NDzU2bhzuN277Zq85vDdfiquX4klh14ehKHE6xo2qZIzgtJRuCQwXFS5Ko5_elDQLjzDYRvOC4qxw9S41_FaMXivsBpDUHHjkx9dP_9zuGES0je4uLwbNVjCdrRDkEFMS0CyWzA7HzOpcMsbSKMqFljzjuQLbtI3HIagwFZylPNTCojLKlLlQpSIZsx20WA5LtYcwjwXRVIICrUHHOiU6jiAkGRCjLGK9j3b9vSYvvoFGwgQAMF7fR57Cs42fiMRSJrGUSRxlkm676xYH_wWcopXWoNtJOu3e9SFapcYj8dmKR2hxPHpVx8ajGGcnjmW-Aboewes
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1JT8JAFJ4YjcaLcRfXOXikhlnamR4JQkCBEBHjrWk7M6bRFEKBhJs_wYt_0F_iLKDEm5dmkslrk3l7573vAXAdC5kGFUU9YTId7SGEl-hAWWcpXGqBUilmpsG50w2aA3r37C-rCU0vjMOH-PnhZjTD2muj4COhVpQcEco9LXLoBhFkWsk37JWfAXemvd-cC3OHIMV9zzj3BbqPKeb584IVF7Qaplo_09gFO4sAEVYdR_fAmsz3waYbGTk_AJ_dr_ePl7d5OizmrowNDhXUURzsVx_6eq82fNJPDItR9iqhhWHIchhPYLXICUEwzoVdUgKzAma5Nk8zKfTCUWjaaq2OYZLZdpcynGXjaQHt_JGyJR676fWLL7famiI4BING_bHW9BajFbyUhhh5OAkFMbMxkwoThJA4CFKuBEtYKqnBbGOhT6Ufc0Zi5ituqBJMpD5QKQMRkiOwng9zeQIgCzlSWFBJlaIqVDFSYUB9lFCkbUWoSuDYnWs0cvgZEeGUUsIqJeAY_LOxTEgMZyLDmchyJuq0OnZx-l-CK7DVu21E7Vb3_gxsYx2PuFrFc7A-GU_lhY4nJsmllZhvyR3BHQ
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=N%E2%80%90glycosylation+of+the+SARS%E2%80%90CoV%E2%80%902+spike+protein+at+Asn331+and+Asn343+is+involved+in+spike%E2%80%90ACE2+binding%2C+virus+entry%2C+and+regulation+of+IL%E2%80%906&rft.jtitle=Microbiology+and+immunology&rft.au=Das%2C+Tuhin&rft.au=Luo%2C+Shuhong&rft.au=Tang%2C+Hao&rft.au=Fang%2C+Jianmin&rft.date=2024-05-01&rft.issn=0385-5600&rft.eissn=1348-0421&rft.volume=68&rft.issue=5&rft.spage=165&rft.epage=178&rft_id=info:doi/10.1111%2F1348-0421.13121&rft.externalDBID=10.1111%252F1348-0421.13121&rft.externalDocID=MIM13121
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0385-5600&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0385-5600&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0385-5600&client=summon